Department of Molecular Medicine, Faculty of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Stem Cell Institute, Department of Development and Regeneration, University of Leuven (KULeuven), Leuven, Belgium.
Stem Cells Dev. 2021 Jul 15;30(14):714-724. doi: 10.1089/scd.2020.0199. Epub 2021 Jun 8.
Autosomal recessive hypercholesterolemia (ARH) is a rare monogenic disorder caused by pathogenic variants in the low-density lipoprotein receptor (LDLR) adaptor protein 1 () gene, encoding for the LDLRAP1 protein, which impairs internalization of hepatic LDLR. There are variable responses of ARH patients to treatment and the pathophysiological mechanism(s) for this variability remains unclear. This is in part caused by absence of reliable cellular models to evaluate the effect of mutations on the LDLRAP1 protein function and its role in LDLR internalization. Here, we aimed to validate patient-specific induced pluripotent stem cell (iPSC)-derived hepatocyte-like cells (HLCs) as an appropriate tool to model ARH disease. Fibroblasts from an ARH patient carrying the recently reported nonsense mutation, c.649G>T, were reprogrammed into hiPSCs using Sendai viral vectors. In addition, we used clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) to create an gene (also known as ) knockout in two different human iPSC lines. ARH patient-derived iPSCs, ARH-knockout iPSC lines, and control iPSCs were efficiently differentiated into HLCs. Western blot analysis demonstrated the absence of LDLRAP1 in HLCs derived from patient and knockout iPSCs, and this was associated with a decreased low-density lipoprotein cholesterol (LDL-C) uptake in ARH-mutant/knockout HLCs compared to control HLCs. In conclusion, we determined that the recently described point mutation in induces absence of the LDLRAP1 protein, similar to what is seen following knockout. This causes a decreased, although not fully absent, LDL-uptake in ARH-mutant/knockout HLCs. As knockout of or presence of the point mutation results in absence of LDLRAP1 protein, residual LDL uptake might be regulated by LDLRAP1-independent internalization mechanisms. Patient-specific iPSC-derived HLCs can therefore be a powerful tool to further decipher mutations and function of the protein.
常染色体隐性高胆固醇血症 (ARH) 是一种罕见的单基因疾病,由低密度脂蛋白受体 (LDLR) 衔接蛋白 1 () 基因中的致病性变异引起,该基因编码 LDLRAP1 蛋白,可损害肝脏 LDLR 的内化。ARH 患者对治疗的反应存在差异,其病理生理机制尚不清楚。部分原因是缺乏可靠的细胞模型来评估突变对 LDLRAP1 蛋白功能的影响及其在 LDLR 内化中的作用。在这里,我们旨在验证患者特异性诱导多能干细胞 (iPSC) 衍生的肝细胞样细胞 (HLC) 作为一种合适的工具来模拟 ARH 疾病。使用 Sendai 病毒载体将来自携带最近报道的无义突变 c.649G>T 的 ARH 患者的成纤维细胞重编程为 hiPSC。此外,我们使用成簇规律间隔短回文重复 (CRISPR)/CRISPR 相关蛋白 9 (Cas9) 在两种不同的人 iPSC 系中创建 基因 (也称为 ) 敲除。ARH 患者来源的 iPSC、ARH 敲除 iPSC 系和对照 iPSC 均有效地分化为 HLC。Western blot 分析表明,源自患者和敲除 iPSC 的 HLC 中 LDLRAP1 缺失,与对照 HLC 相比,ARH 突变/敲除 HLC 中的低密度脂蛋白胆固醇 (LDL-C) 摄取减少。总之,我们确定最近描述的 中的点突变导致 LDLRAP1 蛋白缺失,类似于 敲除后观察到的情况。这导致 ARH 突变/敲除 HLC 中的 LDL 摄取减少,尽管并非完全缺失。由于 或存在点突变导致 LDLRAP1 蛋白缺失,残留的 LDL 摄取可能受到 LDLRAP1 非依赖性内化机制的调节。因此,患者特异性 iPSC 衍生的 HLC 可以成为进一步阐明 突变和蛋白功能的有力工具。